glp-1 agonist indications Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes GLP-1 receptor agonists are transforming
Description
2007;30:S4-S41
Breast Cancer EHR Cohort Study Design In the present study, researchers investigated the associations between GLP-1RA use and all-cause mortality and RFS in patients with BC
Example registry listing (obesity + cardiovascular disease) One publicly listed Phase 3 study is NCT05882045 (TRIUMPH-3) , which evaluates efficacy and safety in participants with obesity and established cardiovascular disease
Both contain semaglutide as the active ingredient
& Hansson, G
